Larimar Therapeutics (LRMR) Net Equity Issued and Repurchased (2013 - 2025)

Larimar Therapeutics' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at -$201000.0 for Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$201000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$546000.0 (down 100.34% YoY) and the FY2025 annual result came in at $65.1 million, down 59.78% from the prior year.
• Net Equity Issued and Repurchased was -$201000.0 for Q4 2025 at Larimar Therapeutics, up from -$345000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $162.2 million in Q1 2024 and bottomed at -$345000.0 in Q2 2024.
• A 4-year average of $36.2 million and a median of -$201000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 14681.48% in 2021, while the deepest fall reached 14681.48% in 2021.
• Larimar Therapeutics' Net Equity Issued and Repurchased stood at $19.7 million in 2021, then plunged by 101.61% to -$316000.0 in 2022, then decreased by 9.18% to -$345000.0 in 2024, then soared by 41.74% to -$201000.0 in 2025.
• Business Quant data shows LRMR's Net Equity Issued and Repurchased at -$201000.0 in Q4 2025, -$345000.0 in Q2 2024, and $162.2 million in Q1 2024.